CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
噬血细胞性淋巴组织细胞增生症样细胞因子释放综合征毒性及合并菌血症的后果
英文原题：Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia.
查看英文原题
Consequences of hemophagocytic lymphohistiocytosis-like cytokine release syndrome toxicities and concurrent bacteremia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
严重细菌感染（SBI）可能导致CD19 CAR-T 细胞治疗及细胞因子释放综合征（CRS）出现严重并发症。对于新型CAR-T 细胞构建体相关SBI，或伴有噬血细胞性淋巴组织细胞增多症（HLH）样毒性的CRS合并SBI，其后果和危险因素仍知之甚少。本文报告3例接受CD22 CAR-T 细胞治疗的B细胞急性淋巴细胞白血病患者，他们均发生SBI和CRS相关HLH。血清细胞因子分析显示，即使CRS缓解后，细胞因子仍持续显著升高，提示全身炎症仍在持续。严重炎症状态与SBI并存会导致不良结局；识别并预防炎症持续或许有助于改善患者结局。
展开英文摘要原文
Serious bacterial infections (SBI) can lead to devastating complications with CD19 CAR T cells and cytokine release syndrome (CRS). Little is known about consequences of and risk factors for SBI with novel CAR T-cell constructs or with CRS complicated by HLH-like toxicities.
We report on three patients with B-cell acute lymphoblastic leukemia treated with CD22 CAR T cells who developed SBI and CRS-associated HLH. Serum cytokine profiling revealed sustained elevations well beyond CRS resolution, suggesting ongoing systemic inflammation. Heightened inflammatory states converging with SBI contribute to poor outcomes, and recognition and prevention of extended inflammation may be needed to improve outcomes.
论文信息
- 作者
- Masih KE、Ligon JA、Yates B、Shalabi H、Little L、Islam Z、Ombrello AK、Inglefield J
- 第一作者单位
- Oncogenomics Section, Genetics Branch, Center for Cancer Research (CCR), National Cancer Institute (NCI), NIH, Bethesda, Maryland, USA.United States
- 通讯作者单位
- Pediatric Oncology Branch, CCR, NCI, NIH, Bethesda, Maryland, USA.United States
- 文献类型
- 美国 NIH 院内研究
- 期刊
- Pediatric blood & cancer2021 Oct
- 原文标识
- PubMed 34309174 · DOI 10.1002/pbc.29247
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →